Medication adherence in patients with psychotic disorders: An observational survey involving patients before they switch to long-acting injectable risperidone
PPA. 2015-09-01; : 1333
DOI: 10.2147/PPA.S89748
Read on PubMed
1. Patient Prefer Adherence. 2015 Sep 16;9:1333-41. doi: 10.2147/PPA.S89748.
eCollection 2015.
Medication adherence in patients with psychotic disorders: an observational
survey involving patients before they switch to long-acting injectable
risperidone.
Baylé FJ(1), Tessier A(2), Bouju S(3), Misdrahi D(2).
Author information:
(1)Sainte-Anne Hospital (SHU), Paris V-Descartes University, Paris, France.
(2)Hôpital Charles Perrens, Pôle de Psychiatrie Adulte, Bordeaux University,
Bordeaux, France ; CNRS UMR 5287-INCIA, Bordeaux University, Bordeaux, France.
(3)Janssen-Cilag France, Issy Les Moulineaux, Paris, France.
BACKGROUND: Maintaining antipsychotic therapy in psychosis is important in
preventing relapse. Long-acting depot preparations can prevent covert
non-adherence and thus potentially contribute to better patient outcomes. In
this observational survey the main objective is to evaluate medication adherence
and its determinants for oral treatment in a large sample of patients with
psychosis.
METHODS: In this cross-sectional survey medication adherence for oral treatment
was assessed by patients using the patient-rated Medication Adherence
Questionnaire (MAQ). Data were collected by physicians on patients with a recent
acute psychotic episode before switching to long-acting injectable risperidone.
Other evaluations included disease severity (Clinical Global Impression –
Severity), patients’ insight (Positive and Negative Syndrome Scale item G12),
treatment acceptance (clinician-rated Compliance Rating Scale), and therapeutic
alliance (patient-rated 4-Point ordinal Alliance Scale).
RESULTS: A total of 399 psychiatrists enrolled 1,887 patients (mean age
36.8±11.9 years; 61.6% had schizophrenia). Adherence to oral medication was
“low” in 53.2% of patients, “medium” in 29.5%, and “high” in 17.3%. Of patients
with psychiatrist-rated active acceptance of treatment, 70% had “medium” or
“high” MAQ scores (P